High-Protein Diet for Improving Alcoholic Fatty Liver Disease
NCT07632222 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 74
Last updated 2026-06-29
Summary
Alcohol-associated liver disease (ALD) is a major cause of mortality from malignant liver diseases, accounting for 47.9% of cirrhosis-related deaths and 30% of liver cancer-related deaths annually. In China, both alcohol consumption and the prevalence of ALD (approximately 5.15%) are on the rise, making ALD an increasingly significant health concern for the population. Alcohol-associated fatty liver disease (AFLD), as the initial and most reversible stage of ALD, is primarily characterized by excessive hepatic lipid deposition, mild liver injury accompanied by mild inflammation. It can progressively develop into alcoholic hepatitis, and in some patients, advance to liver fibrosis, cirrhosis, and even hepatocellular carcinoma. Currently, there is a lack of effective clinical treatments for AFLD. Although alcohol abstinence remains the optimal choice for reversing AFLD, it is often difficult for individuals with alcohol dependence to maintain.
A high-protein diet generally refers to a dietary pattern where protein accounts for more than 20% of total energy intake. A protein contribution of 30% is a common ratio in research investigating high-protein dietary interventions for metabolic diseases. Population-based intervention studies have demonstrated that a high-protein diet at this ratio significantly reduces hepatic fat content. For instance, a study published in Gastroenterology (2017) reported that a 6-week isocaloric high-protein diet (macronutrient distribution: 30% protein, 40% carbohydrates, 30% fat) significantly improved hepatic lipid deposition in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM). Research in Diabetologia (2019) showed that a 6-week isocaloric high-protein diet (30% protein, 30% carbohydrates, 40% fat) significantly reduced hepatic fat content in patients with T2DM. Additionally, a study in Liver International (2020) indicated that a 3-week energy-restricted high-protein diet (30% protein, 35%-45% carbohydrates, 25%-30% fat) significantly decreased hepatic fat content in NAFLD patients. Importantly, none of the aforementioned studies reported adverse events associated with the high-protein dietary interventions. Furthermore, a population-based intervention study published in Annals of Internal Medicine revealed that a low-carbohydrate, high-fat diet was more effective than a high-carbohydrate, low-fat diet in reducing hepatic fat content over a 6-month period in patients with NAFLD and T2DM. These findings suggest that increasing the percentage of energy from protein by reducing carbohydrate intake may yield superior improvements. Based on the macronutrient distributions from the referenced population interventions, and considering that a 30% fat energy contribution closely aligns with the typical dietary fat intake of the Chinese AFLD population, we established the macronutrient distribution for the high-protein diet group as 30% protein, 40% carbohydrates, and 30% fat.
This study intends to conduct a randomized controlled trial to investigate the effects of increasing the percentage of energy from protein under an isocaloric dietary pattern on liver function, hepatic fat content, and glucose-lipid metabolism in individuals with AFLD. The aim is to elucidate the mechanisms underlying its beneficial effects on AFLD, thereby providing population-based evidence and strategies for health promotion in this patient group.
Conditions
- Alcohol-associated Fatty Liver Disease
Interventions
- DIETARY_SUPPLEMENT
-
high protein diet
high protein diet
- DIETARY_SUPPLEMENT
-
control diet
control diet
- DIETARY_SUPPLEMENT
-
perilla peptide dietary group
perilla peptide dietary group
Sponsors & Collaborators
-
Harbin Medical University
collaborator OTHER -
Li Lab,MD
lead OTHER_GOV
Principal Investigators
-
Songtao Li · Zhejiang Chinese Medical University
-
Rennan Ren · Harbin Medical University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 30 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-07-01
- Primary Completion
- 2026-12-31
- Completion
- 2027-12-31
More Related Trials
-
Clinical Course and Biomarkers Associated With Nonalcoholic Fatty Liver Disease (NAFLD) in Chinese Patients With Obesity
NCT07662356 ·Status: RECRUITING
-
The Influence of Nutritional Factors on the Prognosis of Liver Cirrhosis Patients and the Exploration of Predictive Models
NCT06328517 ·Status: RECRUITING
-
Validity of Laboratory Biomarkers in Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) and It's Consequences
NCT06908122 ·Status: NOT_YET_RECRUITING
-
Fatty Liver Disease Collaborative Research in China
NCT02391168 ·Status: UNKNOWN
-
Study on the Correlation Between Fat Soluble Vitamins and Non-alcoholic Fatty Liver Disease
NCT06512701 ·Status: RECRUITING
-
Impact of a Probiotic Supplementation With Lifestyle Modification on Liver Steatosis, Fibrosis, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT07400367 ·Status: RECRUITING ·Phase: NA
-
Assessment of Nutritional Status of Patients With Liver Cirrhosis
NCT03242798 ·Status: COMPLETED
-
Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD
NCT04861571 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Risk Factors and Prediction Model for Liver-Related Outcomes in Elderly Patients With Steatotic Liver Disease
NCT07537829 ·Status: COMPLETED
-
A Clinical Trial of Longqi Jiangzhi Decoction Against Non-alcoholic Fatty Liver Disease
NCT07320456 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Development of a Novel Asian Mediterranean Diet and Its Acceptability in NAFLD
NCT06321211 ·Status: COMPLETED
-
The Effect of a High-fat vs. High-sugar Diet on Liver Fat Accumulation and Metabolism
NCT03145350 ·Status: COMPLETED ·Phase: NA
-
Study on Risk Factors and Prognosis of MASLD
NCT07433205 ·Status: COMPLETED
-
The Potential Value and Impact of Diagnostic Biomarkers for MAFLD Using Machine Learning Methods
NCT06061640 ·Status: UNKNOWN
-
Impact of Exercise Intervention for Patients With Non-alcoholic Fatty Liver Disease
NCT04463667 ·Status: UNKNOWN ·Phase: NA
-
Efficacy of 12-week Daytime Restricted Eating on Hepatic Steatosis of Obesity
NCT07378072 ·Status: RECRUITING ·Phase: NA
-
Impact of Dietary Assessment and Intervention on Outcomes in Liver Cirrhosis Patients
NCT05259930 ·Status: RECRUITING ·Phase: NA
-
The Impact of a Dietary Fiber Enriched Diet on the Outcome of Patients with Liver Cirrhosis
NCT06634186 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis
NCT02030977 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Liver Cancer Prevention Randomized Control Trial
NCT05196867 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Liver Diseases in PLWH
NCT04446156 ·Status: UNKNOWN
-
Prognostic Model for MASLD Related Cirrhosis
NCT07082751 ·Status: NOT_YET_RECRUITING
-
Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease
NCT01327443 ·Status: COMPLETED ·Phase: NA
-
Clinical Characteristics of Metabolic Associated Fatty Liver Disease
NCT06325254 ·Status: RECRUITING
-
To Study the Clinical Course and Outcomes of Non-electively Hospitalised Patients of Chronic Liver Disease (CLD) With Hepatic or Extra-hepatic Predominant Organ Failure(s) at 6 Months.
NCT07270809 ·Status: RECRUITING